• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ucb ADR (OP: UCBJY )

    89.12 UNCHANGED
    Streaming Delayed Price Updated: 3:50 PM EDT, Aug 21, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 89.12
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 89.12
    Today's Range 89.12 - 89.12
    52wk Range 34.85 - 89.17
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target
    Tuesday, Longboard Pharmaceuticals Inc (NASDAQ: LBPH) released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of... 
    Via Benzinga
    Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst
    Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics. 
    Via Benzinga

    Performance

    YTD
    +106.06%
    +106.06%
    1 Month
    +13.74%
    +13.74%
    3 Month
    +29.35%
    +29.35%
    6 Month
    +75.09%
    +75.09%
    1 Year
    +100.45%
    +100.45%

    More News

    Read More
    Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts
    Via Benzinga
    FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults
    Via Benzinga
    Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path
    Via Benzinga
    UCB's Rare Childhood Epilepsy Drug Scores FDA Approval
    Via Benzinga
    The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More
    Via Benzinga
    Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane
    Via Benzinga
    The Week Ahead In Biotech (Jan. 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, & More
    Via Talk Markets
    The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More
    Via Benzinga
    UCB's Bispecific Marks Phase 3 Win For Second Psoriatic Arthritis Study
    Via Benzinga
    ZGNX Stock: The $1.9B UCB Deal That Has Zogenix Shares Zooming Higher Today
    Via InvestorPlace
    Benzinga's Top Ratings Upgrades, Downgrades For September 2, 2021
    Via Benzinga
    UCB Gets EU Approval For Bimekizumab In Psoriasis
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For August 23, 2021
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For July 23, 2021
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For July 9, 2021
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.